Arterial hypertension assessment in a population with chronic myeloid leukemia
Abstract Treatment of chronic myeloid leukaemia (CML) is based on tyrosine kinase inhibitors (TKI), whose introduction in 2001 improved the survival rate after 5 years from 40 to 90%. The longevity increase has been accompanied by a higher incidence of cardiovascular events (CVE) that can be explain...
Guardado en:
Autores principales: | Ricardo Roa-Chamorro, Fernando Jaén-Águila, José Manuel Puerta-Puerta, Lucía Torres-Quintero, Pablo González-Bustos, Juan Diego Mediavilla-García |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f027b0237aed45dd809a0b10112f4dd8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
METABOLIC STATE OF BLOOD LYMPHOCYTES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOID LEUKEMIA
por: O. V. Smirnova, et al.
Publicado: (2014) -
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Radhakrishnan Ramchandren, et al.
Publicado: (2009) -
CHRONIC MYELOID LEUKEMIA - CLINICAL AND IMMUNOLOGICAL PECULIARITIES IN ADULT PATIENTS
por: O. V. Smirnova
Publicado: (2012) -
PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
por: Serap Karaman, et al.
Publicado: (2021) -
Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients
por: Ibuki Harada, et al.
Publicado: (2021)